Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7982340 | 0.89 | MEN1 (0.52) | LMNAMEN1CACNA1BAPBA1KMT2A | |
| SCHEMBL18736526 | 0.82 | HDAC1 (0.50) | KDM4EALDH1A1HPGDEPHX2 | |
| SCHEMBL20606513 | 0.81 | EGFR (0.59) | KDM4EALDH1A1HPGD | |
| SCHEMBL20606528 | 0.81 | HTT (0.57) | LMNAMEN1CACNA1BAPBA1KMT2A | |
| SCHEMBL1768623 | 0.78 | NPC1 (0.69) | LMNAALDH1A1HPGD | |
| SCHEMBL20606393 | 0.78 | SMN1; SMN2 (0.54) | LMNAMEN1KMT2AKDM4E | |
| SCHEMBL31497721 | 0.75 | SMN1; SMN2 (0.60) | MEN1KMT2AHTT | |
| SCHEMBL6617032 | 0.74 | ALOX15 (0.59) | LMNAALDH1A1OPRM1TMEM97SIGMAR1 | |
| SCHEMBL9598312 | 0.74 | MAPK1 (0.56) | LMNAPPARGKDM4EALDH1A1 | |
| SCHEMBL2546886 | 0.74 | RAB9A (0.52) | LMNAMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654231-B1 | CONJUGATE COMPOUNDS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE OR FOR TREATMENT OF SEIZURE DISORDERS | DPHARM LTD (IL) | 2012-02-01 | — | — | EP | disclosed |
| US-7745426-B2 | Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders | D-PHARM LTD. (IL) | 2010-06-29 | — | — | US | disclosed |
| EP-1654231-A4 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE AND/OR FOR TREATMENT OF SEIZURE DISORDERS | DPHARM LTD (IL) | 2009-03-11 | — | — | EP | disclosed |
| US-20060235000-A1 | Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders | D-PHARM LTD. (IL) | 2006-10-19 | — | — | US | disclosed |
| EP-1654231-A2 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE AND/OR FOR TREATMENT OF SEIZURE DISORDERS | D-Pharm Ltd. (IL) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016228-A2 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE AND/OR FOR TREATMENT OF SEIZURE DISORDERS | D-PHARM LTD. (IL) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235000-A1 | Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders | PNPO, CYP2B6, CHRNA6 | LMNA 2634/4885PPARG 1128/4885MEN1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.